Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Anabolic skeletal therapy for osteoporosis Girotra M; Rubin MR; Bilezikian JPArq Bras Endocrinol Metabol 2006[Aug]; 50 (4): 745-54Antiresorptive agents for osteoporosis are a cornerstone of therapy, but anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, anabolic agents reduce fracture incidence by improving bone qualities besides increasing bone mass. In this article, we review the role of anabolic treatment for osteoporosis. The only anabolic agent currently approved in the United States for osteoporosis, teriparatide [recombinant human parathyroid hormone(1-34)], has clearly emerged as a major approach to selected patients with osteoporosis. Teriparatide increases bone density and bone turnover, improves microarchitecture, and changes bone size. The incidence of vertebral and nonvertebral fractures is reduced. Teriparatide is approved for both postmenopausal women and men with osteoporosis who are at high risk for fracture. Other potential anabolic therapies for osteoporosis, including other forms of parathyroid hormone, strontium ranelate, growth hormone, and insulin-like growth factor-1, are also reviewed in this article.|Bone Density Conservation Agents/pharmacology/*therapeutic use[MESH]|Bone Density/*drug effects[MESH]|Clinical Trials as Topic[MESH]|Female[MESH]|Fractures, Bone/etiology/prevention & control[MESH]|Growth Hormone/therapeutic use[MESH]|Humans[MESH]|Insulin-Like Growth Factor I/therapeutic use[MESH]|Male[MESH]|Organometallic Compounds/therapeutic use[MESH]|Osteoporosis, Postmenopausal/complications/drug therapy[MESH]|Osteoporosis/*drug therapy[MESH]|Parathyroid Hormone/therapeutic use[MESH]|Risk Factors[MESH]|Teriparatide/pharmacology/*therapeutic use[MESH]|Thiophenes/therapeutic use[MESH] |
